EU Regulator Backs Oral and High-Dose Wegovy as US Sales Exceed Forecasts
The Committee for Medicinal Products for Human Use issued positive opinions for two new Wegovy formulations. These endorsements cover a 25 mg oral tablet and a 7.2 mg single dose injector pen. This oral tablet represents the first GLP-1 receptor agonist for weight management in this specific format. Formal ratification from the governing commission typically follows these recommendations.
The regulatory support for the oral version stems from the OASIS-4 clinical trial. Participants achieved a mean body weight reduction of 16.6 percent. Notably, one third of the trial population exceeded 20 percent weight loss. Given this, the tablet carries no drug interaction restrictions for patients.
The high dose injector pen demonstrated strong efficacy in the STEP-UP study. Patients with obesity achieved a mean weight reduction of 20.7 percent. Roughly one third of these individuals reached at least 25 percent loss. Along with this, the pen simplifies the weekly treatment burden significantly.
Initial sales in the national market reached 2.3 billion Danish kroner. This figure doubled the consensus projections from industry analysts. Over 1.3 million prescriptions were generated in the first quarter alone. Building on this, 80 percent of users had no prior GLP-1 exposure.
Competitive pressure remains substantial within the obesity therapy sector. A rival firm recently received approval for an oral therapy with no fasting requirements. By contrast, semaglutide requires a 30 minute wait before eating. Therefore, this administration requirement creates a practical disadvantage for patient adherence.
Market valuations currently reflect these complex competitive dynamics. One manufacturer trades at a price to earnings ratio of approximately 13. Meanwhile, the primary competitor commands a ratio near 29. Accordingly, markets price these assets based on current commercial performance rather than potential.
Research continues into metabolic dysfunction associated with steatohepatitis. This new indication would extend clinical utility beyond weight management. New data presentations will occur at an upcoming liver study congress. Consequently, the midyear financial results will signal future commercial momentum.
Furthermore, manufacturing capacity remains a critical focal point for global leadership. The company is investing billions to expand specialized fill-finish facilities. These upgrades aim to alleviate persistent shortages in the supply chain. Thus, successful scaling will determine the ultimate market share.
Moreover, insurance coverage policies continue to evolve across various national markets. Federal health agencies are currently reviewing the long-term cost benefits of these treatments. Positive cardiovascular outcome data often influence these reimbursement decisions. Hence, broader access depends on sustained clinical evidence.
In light of this, the company is diversifying its metabolic research portfolio. Scientists are investigating combination therapies to preserve lean muscle mass during weight loss. These efforts address a significant unmet need in chronic weight management. Building on this, early phase results show promise for next-generation compounds.
Meanwhile, national pharmacies report strong uptake following a major advertising campaign. Over 70,000 pharmacies currently stock the new tablet formulation. Recent data indicates over 200,000 weekly prescriptions in the national market. In view of this, the product has achieved blockbuster status within four months.
Accordingly, federal agencies recently expanded access to these treatments for eligible participants. This policy change applies to patients with documented cardiovascular disease and obesity. Furthermore, price reductions in early 2026 have improved affordability for self-pay users. Thus, lower costs are attracting patients away from unregulated compounded alternatives.
